I don't think we should be too surprised that the FDA's major sticking point looks like the dystrophin quantitation data.
Honestly I'm still floored by the shoddy data SRPT released to the public in this regard. Was it willful disregard, laziness or just outright ineptitude?
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.